People are underestimating the significance of drug pricing provisions in Inflation Reduction Act Rena M. Conti, Leslie Dach, and Richard G. Frank Thursday, October 13, 2022
Comments on the Request for Information on Medicare Loren Adler, Matthew Fiedler, Richard G. Frank, and Marta E. Wosińska Wednesday, September 7, 2022
Auditing the prescription drug Consumer Price Index Richard G. Frank, Ernst R. Berndt, and Andrew L. Hicks Friday, August 26, 2022
Accelerated approval of cancer drugs: No economic reward for drug makers that conduct confirmatory trials Richard G. Frank, Ezekiel Emanuel, and Mahnum Shahzad Thursday, August 18, 2022
Familiar complaints and distortions with little merit from the pharmaceutical industry Richard G. Frank Thursday, August 11, 2022
International reference pricing in the context of U.S. drug policy Richard G. Frank, Rena M. Conti, and Jonathan Gruber Tuesday, July 26, 2022
Toward great accountability in mental health care Richard G. Frank and Ruth Shim Monday, July 18, 2022
Profits, medical loss ratios, and the ownership structure of Medicare Advantage plans Richard G. Frank and Conrad Milhaupt Wednesday, July 13, 2022
The Senate’s plan on insulin drugs is the wrong way to solve the affordability problem Richard G. Frank and Marta E. Wosińska Thursday, July 7, 2022
To prevent public health crises, we need to update the essential medical product list Marta E. Wosińska and Richard G. Frank Friday, June 24, 2022